NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Clinical hold/Recruitment or enrollment suspended
Gender: Male & Female
Min Age: 18 Years
Max Age: 100 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


Immune Checkpoint Inhibitor;
TKI inhibitors;
Advanced soft tissue sarcoma

Recruitment Keyword(s)



Advanced soft tissue sarcoma

Investigational Drug(s)

XL184 (cabozantinib-s-malate)
BMS-734016 (ipilimumab)

Investigational Device(s)



Drug: Cabozantinib
Drug: Ipilimumab
Drug: Nivolumab

Supporting Site

National Cancer Institute


Soft tissue sarcomas (STS) are rare cancers that affect the skin and connective tissue. People with STS typically survive only 18 to 24 months after diagnosis. Better treatments are needed.


To test a new combination of drugs (cabozantinib, ipilimumab, and nivolumab) in people with STS.


People aged 18 years or older with STS, specifically metastatic undifferentiated pleomorphic sarcoma (UPS), extraskeletal myxoid chondrosarcoma (EMC), liposarcoma (LPS), or non-uterine leiomyosarcoma (LMS).


Participants will be screened. They will have blood tests and a test of their heart function. They will have imaging scans. They will have a biopsy: A sample of tissue will be removed from their tumor with a thin needle.

Participants will be divided into 2 groups. Some will receive 2 drugs (ipilimumab and nivolumab); others will receive both of those drugs plus a 3rd one (cabozantinib).

Ipilimumab and nivolumab are given through a tube attached to a needle inserted into a vein in the arm. All participants will receive these drugs on the first day of four 3-week treatment cycles. After that, they will receive nivolumab alone on the first day of 4-week treatment cycles.

Cabozantinib is a tablet taken by mouth. Some participants will take this drug once a day at home throughout the study. They will write down when they take each dose in a pill diary. These participants will also need to take their blood pressure every day and record those numbers in their diary.

Biopsies, imaging scans, and other tests will be repeated at some study visits. If their cancer gets worse, participants taking only 2 drugs may cross over and begin taking the cabozantinib too.

Participants may continue treatment as long as the drugs are helping them.

--Back to Top--



1. Patients must have histologically or cytologically confirmed metastatic STS, specifically undifferentiated pleomorphic sarcoma (UPS), extraskeletal myxoid chondrosarcoma (EMC), liposarcoma (LPS) or non-uterine leiomyosarcoma (LMS) that are locally advanced and surgically unresectable.

2. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >=20 mm (>=2 cm) by chest x-ray or as >=10 mm (>=1 cm) with CT scan, MRI, or calipers by clinical exam. Disease will be measured by RECISTv1.1.

3. Patients with prior treatment with MET or VEGFR inhibitors are allowed. However, prior cabozantinib-treated patients will not be allowed. Prior ipilimumab in combination with nivolumab-treated patients will not be allowed.

4. Age >=18 years.

5. ECOG performance status <=2 (Karnofsky >=60%)

6. Patients must have adequate organ and marrow function as defined below:

- absolute neutrophil count >=1,000/mcL

- platelets >=75,000/mcL

- total bilirubin <= 1.5 x institutional upper limit of normal (ULN)

- AST(SGOT)/ALT(SGPT) <=3 x institutional ULN

- Creatinine <= 1.5x institutional ULN OR

- glomerular filtration rate (GFR) >=50 mL/min/1.73 m2

- serum albumin >=2.8g/dL

- lipase <2.0 x ULN and no radiologic or clinical evidence of pancreatitis

- urine protein/creatinine ratio (UPCR) <=1

7. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy if indicated.

8. Patients with a history of hepatitis C virus (HCV) infection must have been treated and undetectable HCV viral load 12 or more weeks after treatment completion. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

9. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression >=1 month after treatment of the brain metastases. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first 2 cycles of therapy.

10. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.

11. Patients must be willing to provide blood specimens and undergo biopsies for research purposes.

12. Patients with baseline blood pressure (BP) lower than 140 mmHg (systolic) and 90 mmHg (diastolic). Patients on >2 anti-hypertensive agents will be excluded.

13. Human immunodeficiency virus (HIV)-infected patients on effective combination antiretroviral therapy are eligible as long as HIV is well- controlled and there is undetectable viral load within 6 months. For these patients, an HIV viral load test must be completed within 28 days prior to enrollment.

14. The effects of nivolumab, ipilimumab, and cabozantinib on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP (defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal) should use an adequate method to avoid pregnancy for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) at the time of enrollment and within 8 days prior to each cycle. Women must not be breastfeeding.

15. Men who are sexually active with women of child-bearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year. Men receiving cabozantinib and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 5 months after the last dose of investigational product. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception.

16. Ability to understand and the willingness to sign a written informed consent document.


1. Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia, stable hyperthyroidism on replacement therapy, type-1 diabetes, well-controlled insulin, and non-clinically significant toxicities at the discretion of the study Principal Investigator.

2. Patients who are receiving any other investigational agents.

3. Eligibility of subjects receiving any medications or substances known to affect or with the potential to affect the activity of cabozantinib will be determined following review of their cases by the Principal Investigator. Patients who are taking enzyme-inducing anticonvulsant agents are not eligible.

4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, or ipilimumab.

5. Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John s Wort) are not allowed for this study. Because the lists of these agents are constantly changing, frequently updated lists available at or other reliable resources will be consulted. Patients who need to come off CYP3A4 inhibitors/inducers should adhere to a washout period of at least 5 times the half-life of the CYP3A4 inhibitors and 14 days of CYP3A4 inducers.

6. Patients with any other significant condition(s) that would make this protocol unreasonably hazardous are ineligible. Patients with uncontrolled intercurrent illness or clinical evidence of an active infection at the time of enrollment are ineligible.

7. Pregnant women are excluded from this study because cabozantinib is a receptor kinase inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib in combination with nivolumab and ipilimumab, breastfeeding should be discontinued if the mother is treated with cabozantinib. These potential risks may also apply to other immunotherapeutic agents (ipilimumab and nivolumab) used in this study.

8. Patients that require concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel). Low dose aspirin (<=81 mg/day), low-dose warfarin (<=1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted. (Please note that there may be cases in which patients on study require anticoagulation for DVT/PE management; this does not necessitate taking the patient off study.

9. Patients with any of the following within 12 weeks prior to the first dose of cabozantinib: gastrointestinal bleeding, hemoptysis or pulmonary hemorrhage, radiographic evidence of cavitating pulmonary lesion(s), evidence of tumor invasion of the GI tract (esophagus, stomach, small or large bowel, rectum, or anus), or any evidence of endotracheal or endobronchial tumor or encasement of any major blood vessels.

10. The patient is unable to swallow tablets.

11. The patient has a corrected QT interval calculated by the Fridericia formula (QTcF) >=470 ms within 28 days before enrollment.

12. Patients with a requirement for steroid or immunosuppressive treatment should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Alice P. Chen, M.D.
National Cancer Institute (NCI)
(240) 781-3320

Ashley B. Bruns
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 8D53
10 Center Drive
Bethesda, Maryland 20892
(240) 858-3162

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--